 Mitogen-Activated Protein Kinase Kinases
"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
| Descriptor ID |
D020929
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
|
| Concept/Terms |
Mitogen-Activated Protein Kinase Kinases- Mitogen-Activated Protein Kinase Kinases
- Mitogen Activated Protein Kinase Kinases
- MAPKKs
- MAPK Kinases
- Kinases, MAPK
- MAPKK
- Map Kinase Kinase
- Kinase Kinase, Map
- Kinase, Map Kinase
- MAP Kinase Kinases
- Kinase Kinases, MAP
- Kinases, MAP Kinase
MAPK-ERK Kinases- MAPK-ERK Kinases
- Kinases, MAPK-ERK
- MAPK ERK Kinases
- MEKs
- MAP-ERK Kinase
- Kinase, MAP-ERK
- MAP ERK Kinase
|
Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".
This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 0 | 2 | 2 | | 1997 | 3 | 0 | 3 | | 1998 | 2 | 0 | 2 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 5 | 6 | | 2001 | 2 | 4 | 6 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 2 | 3 | | 2004 | 2 | 2 | 4 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 2 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 2 | 3 | | 2012 | 1 | 2 | 3 | | 2013 | 2 | 1 | 3 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 1 | 2 | 3 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.
-
Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, Allen JC, Schorry E, Korf B, Robison NJ, Goldman S, Vinks AA, Emoto C, Fukuda T, Robinson CT, Cutter G, Edwards L, Dombi E, Ratner N, Packer R, Fisher MJ. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
-
Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJ. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.
-
Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma. Neurologist. 2018 Sep; 23(5):163-166.
-
Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018 07; 24(7):968-977.
-
Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 2017 Mar; 108(3):488-496.
-
Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 03 16; 543(7645):378-384.
-
Reddy MGS, Dony E. Role of aquaporins in oral cancer. J Cancer Res Ther. 2017 Jan-Mar; 13(1):137-138.
-
Gonzalez AM, Hoffman JR, Townsend JR, Jajtner AR, Boone CH, Beyer KS, Baker KM, Wells AJ, Mangine GT, Robinson EH, Church DD, Oliveira LP, Fukuda DH, Stout JR. Intramuscular MAPK signaling following high volume and high intensity resistance exercise protocols in trained men. Eur J Appl Physiol. 2016 Sep; 116(9):1663-70.
-
Ikeda Y, Park JH, Miyamoto T, Takamatsu N, Kato T, Iwasa A, Okabe S, Imai Y, Fujiwara K, Nakamura Y, Hasegawa K. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6110-6117.
-
Kato T, Inoue H, Imoto S, Tamada Y, Miyamoto T, Matsuo Y, Nakamura Y, Park JH. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget. 2016 Apr 05; 7(14):17652-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|